In-vitro diagnostics (IVDs) are a vital part of today’s healthcare system. It is used to diagnose, screen, scan, and assess predispositions to diseases monitoring. They are thereby contributing to the available medical information regarding a patient. Further allowing earlier and more targeted treatments, IVDs help reduce hospital stays; reduce costs and economic growth in the long run. As per the Renub Research report, the France In-Vitro Diagnostics market is expected to reach US$ 2.1 Billion by the end of the year 2026.
The Market for In-Vitro Diagnostic is a dynamic sector in the French medical market. Currently, the industry is undergoing significant changes. However, as the country struggles with the ever-increasing financial burdens of an ageing population and a comprehensive national health care system, the requirements of leveraging the cost/benefit advantages of effective diagnostics are becoming more and more visible in the industry.
Another important IVD market in France is
